生命科学资讯
生物技术与制药领域的最新动态
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
Thermo Fisher推出蛋白质、DNA与RNA顺序提取试剂盒 - 合同制药
Thermo Fisher Launches Kit for Sequential Protein, DNA and RNA Extraction - Contract Pharma
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Reversal on Moderna's flu application follows atypical path through FDA
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Faeth goes public in merger with Sensei, nets $200M in stock sale
Pharma could be on the cusp of finally breaking the blood-brain barrier
AI is slashing jobs across industries. Will pharma be next?
FDA reverses course, will review Moderna’s flu vaccine
CRB recruits construction leader after wave of leadership changes - The Business Journals
巨型DNA病毒编码真核生物标志性翻译起始复合体
Giant DNA viruses encode a hallmark translation initiation complex of eukaryotic life
丹纳赫以99亿美元收购患者监护专家马西莫。
Danaher buys patient monitoring specialist Masimo in $9.9B deal
礼来支付CSL 1亿美元预付款，购买在器官移植三期研究中失败的IL-6抗体。
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
科萨纳携1.75亿美元及抗淀粉样蛋白抗体进军拥挤的阿尔茨海默病领域
Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
礼来以1亿美元预付款获得CSL的IL-6免疫炎症抗体许可。
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Paragon新生物技术公司Korsana挑战阿尔茨海默病，与罗氏一较高下。
Paragon's new biotech Korsana tackles Alzheimer's like Roche